What Marcan Pharmaceuticals does

Marcan Pharmaceuticals Inc. is a privately held Canadian generic pharmaceutical company headquartered in Ottawa, Ontario, and a wholly-owned subsidiary of Emcure Pharmaceuticals Ltd. since 2015. The company develops, markets, and distributes a portfolio of 170+ generic medications spanning oral solids and injectable formulations, with therapeutic coverage including oncology, cardiology, neurology, anti-infectives, psychiatry, endocrinology, and immunology. Vertical integration with parent Emcure provides access to 89 Active Pharmaceutical Ingredients and manufacturing capacity, while Marcan itself operates the Canadian regulatory, sales, and distribution layer with Health Canada Drug Identification Numbers on each product. Following the July 2026 CAD $50 million full acquisition of Mantra Pharma Inc., Marcan also owns the Quebec-based prescription drug and natural health product distribution subsidiary.

The company operates a B2B enterprise go-to-market with a dedicated Hospital & Institutional business unit supplying 150+ SKUs to 1,200+ hospitals across Canada, plus broader distribution reaching 1,000+ retail pharmacies and 700+ hospital pharmacies. Regional sales coverage spans Ontario, Western Canada, and Quebec through Account Managers reporting to a Senior Director National Sales, with regulatory affairs specialists supporting provincial formulary inclusion and Health Canada compliance. Patient support programs tied to specialty products (MAR-Fingolimod, MAR-Dimethyl Fumarate, MAR-Teriflunomide) provide reimbursement and co-pay assistance.

Revenue is generated through pharmaceutical product sales at regulated Canadian prices negotiated via provincial formularies and the pan-Canadian Pharmaceutical Alliance (pCPA). The portfolio is sold primarily through one-time B2B purchase transactions with pharmacy and institutional buyers rather than subscription or licensing models. With a 50+ employee workforce (more than double the prior 20-person base) and a sustained product launch cadence across multiple therapeutic categories, Marcan is in active scaling mode, though the February 2026 MAR-Amlodipine recall highlights quality-control risks inherent in generic manufacturing.

Name

Marcan Pharmaceuticals

Legal name

Marcan Pharmaceuticals Inc.

Website

https://marcanpharma.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Marcan Pharmaceuticals is an Ottawa-based generic drug distributor and subsidiary of India's Emcure Pharmaceuticals, marketing 170+ medications across oncology, neurology, cardiology, and anti-infectives to 1,200+ Canadian hospitals and 1,000+ retail pharmacies, now including Quebec subsidiary Mantra Pharma.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceuticals distribution
• Hospital pharmaceutical supply
• Branded generic medications
• Injectable pharmaceutical products
• Retail pharmacy distribution

Headquarters

HQ city

Ottawa

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

1. Generic Pharmaceutical Sales: Manufacturing and distribution of branded and generic pharmaceutical products for the Canadian market. Products sold to retail pharmacies, hospital pharmacies, and healthcare institutions through B2B sales relationships.
2. Prescription Drug Distribution: Marketing and distribution of prescription drugs and natural health products through Mantra Pharma Inc. (Quebec-based subsidiary).

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Marcan Pharmaceuticals Inc. develops, manufactures, and distributes a portfolio of 170+ generic and branded-generic pharmaceutical products for the Canadian market, including oral and injectable dosage forms. The company operates two primary business lines — a Hospital & Institutional unit supplying over 150 SKUs to more than 1,200 hospitals, and a Retail Pharmacy distribution channel reaching over 1,000 retail pharmacies — leveraging vertically integrated manufacturing through its parent Emcure Pharmaceuticals.

Product overview

Marcan Pharmaceuticals Inc. is an Ottawa-based pharmaceutical company that develops, manufactures, and distributes generic pharmaceutical products for the Canadian market. The company operates as a subsidiary of Emcure Pharmaceuticals Ltd. following acquisition in 2015. Marcan's product portfolio consists of 170+ generic medications covering diverse therapeutic categories including antianginals, antidepressants, anticonvulsants, antibiotics, antineoplastics, antihistamines, and more. Products are available in multiple dosage forms including oral tablets, capsules, and injectable formulations. The company serves both retail and hospital pharmacies (over 1,100 retail and 700+ hospital pharmacies), and offers patient support programs for specialty medications like MAR-Fingolimod, MAR-Dimethyl Fumarate, and MAR-Teriflunomide. The portfolio includes branded generics (prefixed with 'MAR-') and pure generic formulations, with the Hospital & Institutional business unit providing over 150 SKUs to over 1,200 hospitals in Canada.

Differentiator

Problem solved

Functional benefit

Brands

• Mantra Pharma Inc. Subsidiary engaged in marketing and distribution of prescription drugs and natural health products in Canada, incorporated in Quebec.

Products and services

• MAR-Ranolazine XR Extended-release antianginal tablets (500 mg) used to treat chronic angina. Distributed to Canadian retail and hospital pharmacies.
• Treosulfan for Injection Antineoplastic alkylating agent injectable (5 g/vial) used in conditioning treatment prior to hematopoietic stem cell transplantation.
• MAR-ZOLMITRIPTAN 5-HT1 receptor agonist tablets (2.5 mg) used for acute migraine treatment.
• MAR-DOXEPIN Tricyclic antidepressant/anxiolytic capsules (10–100 mg) for depression and anxiety disorders.
• MAR-DIENOGEST Progestin tablets (2 mg) used for the treatment of endometriosis.
• Arsenic Trioxide for Injection Antineoplastic injectable (10 mL vial) used in the treatment of acute promyelocytic leukemia.
• MAR-FLUOXETINE SSRI antidepressant capsules (10 mg, 20 mg) for depression, OCD, and bulimia.
• MAR-AFATINIB Protein kinase inhibitor tablets (20–40 mg) for non-small cell lung cancer treatment.
• MAR-LEFLUNOMIDE Antirheumatic/immunomodulator tablets (10 mg, 20 mg) for rheumatoid arthritis.
• MAR-BILASTINE Second-generation antihistamine tablets (20 mg) for allergic rhinitis and urticaria.
• MAR-METFORMIN XR Extended-release oral antihyperglycemic tablets (500 mg, 1000 mg) for type 2 diabetes management.
• MAR-ESZOPICLONE Non-benzodiazepine hypnotic tablets (1–3 mg) for the treatment of insomnia.
• Vancomycin Hydrochloride for Injection USP Antibiotic injection (500 mg, 1 g, 5 g vials) for treatment of serious gram-positive bacterial infections.
• MAR-ETHOSUXIMIDE Anticonvulsant capsules (250 mg) used in the treatment of absence seizures.
• Colistimethate for Injection USP Polymyxin antibiotic injection (150 mg/vial) for treatment of multi-drug resistant gram-negative bacterial infections.
• BiCNU Carmustine for Injection Antineoplastic sterile powder for reconstitution (100 mg) used in chemotherapy treatment regimens.
• acetaZOLAMIDE for Injection USP Carbonic anhydrase inhibitor diuretic sterile powder for injection (500 mg/vial) for IV use.
• MAR-METFORMIN Immediate-release oral antihyperglycemic tablets (500 mg, 850 mg) for type 2 diabetes management.
• MILRINONE LACTATE INJECTION USP Inotropic/vasodilator injection (10 mg/10 mL) for short-term treatment of acute decompensated heart failure.
• MAR-CYPROHEPTADINE First-generation antihistamine tablets (4 mg) used for allergy relief and appetite stimulation.
• PROPOFOL INJECTION General anesthetic injectable emulsion (200–1000 mg vials) for induction and maintenance of anesthesia.
• MAR-APIXABAN Direct oral anticoagulant tablets (2.5 mg, 5 mg) for prevention of stroke and blood clots.
• MAR-CLONIDINE Alpha-2 agonist tablets (0.025 mg) for management of menopausal vasomotor symptoms.
• MAR-ONDANSETRON ODT 5-HT3 receptor antagonist orally disintegrating tablets (4 mg, 8 mg) for prevention of nausea and vomiting.
• MAR-MYCOPHENOLATE MOFETIL Immunosuppressive oral suspension (200 mg/mL) used to prevent organ transplant rejection.
• ONDANSETRON INJECTION USP Antiemetic sterile solution for IV injection (40 mg/20 mL) for prevention of chemotherapy-induced nausea.
• MAR-DIMETHYL FUMARATE Immunomodulating delayed-release capsules (120 mg, 240 mg) for multiple sclerosis treatment.
• PENTAMIDINE ISETIONATE FOR INJECTION BP Antimicrobial injection (300 mg/vial) for treatment and prevention of Pneumocystis pneumonia.
• MAR-Amlodipine Calcium channel blocker antihypertensive tablets (2.5–10 mg) for hypertension and angina management.
• MAR-Fingolimod S1P receptor modulator capsules (0.5 mg) for relapsing-remitting multiple sclerosis, with patient support program.
• MAR-Teriflunomide Immunomodulator for multiple sclerosis management with risk management plan and patient educational materials.

Quantifiable outcome

• Fourfold growth compared to the Canadian market benchmark
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Mantra Pharma Inc.coreStrategic or Co-development Partner · 2 July 2026Marcan Pharmaceuticals acquired 100% of Class E Special Shares in Mantra Pharma Inc. for CAD $50 million. Transaction completed July 2, 2026, consolidating full ownership of Mantra under Marcan. Mantra Pharma, incorporated in Quebec, Canada, is engaged in marketing and distribution of prescription drugs and natural health products with reported turnover of CAD 96.67 million in FY2026.
• Emcure Pharmaceuticals Ltd.coreOthers · 1 January 2015Marcan was acquired by Emcure Pharmaceuticals Ltd. in 2015. Emcure is a vertically integrated global manufacturer and R&D leader. Through this partnership, Marcan continues to focus on development and growth of its Canadian portfolio with access to manufacturing capabilities.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• SteriMax Inc. Canadian specialty pharmaceutical company with strong focus on sterile injectable products for hospital and institutional markets. Comparable in the injectable niche that Marcan has been growing with 85+ injectable SKUs.

Direct peers

• Apotex Inc. Canada's largest generic pharmaceutical manufacturer, headquartered in Toronto. Directly comparable as a generic pharma developer and distributor serving Canadian retail pharmacies, hospital formularies, and global markets with overlapping therapeutic categories.
• Pharmascience Inc. Privately held Canadian generic pharmaceutical company based in Montreal, Quebec. Direct peer serving similar retail pharmacy and hospital channels across Canada with comparable branded generic (pms-) portfolios and therapeutic coverage.
• JAMP Pharma Group: Canadian-owned generic pharmaceutical company focused on prescription generics, OTCs, and consumer health products. Direct competitor in the Canadian retail pharmacy and institutional channels across overlapping molecules.
• Lupin Pharmaceuticals Canada: Indian-headquartered generic pharmaceutical company with Canadian operations distributing branded and generic products to retail and hospital channels. Directly comparable vertically-integrated emerging-market manufacturer expanding in Canada.
• Aurobindo Pharma Ltd. Vertically integrated Indian generic manufacturer comparable to Marcan's parent Emcure. Uses a similar export-oriented model supplying finished dosages and APIs to regulated markets including North America, with overlapping molecule coverage in oncology, cardiovascular, and anti-infectives.
• Mint Pharmaceuticals Inc. Canadian specialty generic pharmaceutical company headquartered in Mississauga, Ontario. Comparable as a mid-sized Canadian generic distributor serving hospital and retail markets with similar branded generic positioning.

Broad incumbents

• Teva Pharmaceutical Industries Ltd. (Canada): Global generic pharmaceutical leader with substantial Canadian operations. Competes with Marcan across overlapping generic molecules sold to Canadian retail pharmacies and hospitals, but operates at much larger scale and broader international footprint.
• Hikma Pharmaceuticals (Canada): Global generic and specialty pharmaceutical manufacturer with Canadian operations, particularly strong in injectables. Competes with Marcan across hospital injectable and oral generic categories in the Canadian market.
• Sandoz (Novartis) Canada: Sandoz is the world's largest generics company following its spin-off from Novartis and maintains a strong Canadian presence. Broad incumbent competing in the same hospital and retail generic channels that Marcan serves, across comparable therapeutic categories including injectables.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/marcan-pharmaceuticals-inc-
• Xx.com/MarcanPharma

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marcan Pharmaceuticals